Investigation on the anti-obesity effects of research food intake - Investigation on the anti-obesity effects of research food intake

Metagen, Inc.0 sites20 target enrollmentMarch 29, 2024

Overview

Phase: 未知
Intervention: Not specified
Conditions: Not specified
Sponsor: Metagen, Inc.
Enrollment: 20
Status: Not yet recruiting
Last Updated: last year

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

No summary available.

Registry

who.int

Start Date

March 29, 2024

End Date

August 4, 2024

Last Updated

last year

Study Type

Interventional

Sex

All

Investigators

Sponsor

Metagen, Inc.

Eligibility Criteria

Inclusion Criteria

Not provided

Exclusion Criteria

•(1\) Subjects who are unable to discontinue consumption of foods for specified health uses, foods with function claims, health foods (including supplements) that may affect the research (anti\-obesity, lipid metabolism, appetite control, intestinal regulation, etc.) from the time consent is obtained. (2\) Subjects who have taken drugs (antibiotics, antiflatulent, laxatives, etc.) that would affect the study one month prior to the pre\-test. (3\) Subjects who plan to take drugs that will affect the research during the study. (4\) Subjects with a history of appendectomy. (5\) Subjects who have undergone surgery that may affect the study (colonoscopy, removal of gallstones or gall bladder, gastric bypass surgery, bariatric surgery, etc.) within 6 months prior to obtaining consent. (6\) Subjects undergoing dietary restriction or weight loss. (7\) Subjects who plan to lose weight during the study. (8\) Subjects who are expected to undergo a major change in their family, work, or other living environment (e.g., relocation, transfer, etc.) during the study. (9\) Subjects with extremely irregular eating habits. (10\) Subjects with special dietary habits (vegetarian, vegan, low\-carbo). (11\) Subjects whose roommates plan to participate in the study. (12\) Smokers. (13\) Heavy alcohol drinkers. (14\) Subjects with previously diagnosed diabetes mellitus (type 1/type 2\) or dyslipidemia. (15\) Subjects with a history of serious diseases of the heart, liver, kidneys, digestive organs, etc. (16\) Pregnant, lactating, or intending to become pregnant during the study. (17\) Subjects allergic to medicines and foods. (18\) Subjects who are aware of excessive abdominal symptoms (severe diarrhea or bloating) when ingesting oligosaccharides. (Due to character limitation, the following will be listed in the "Others" section)